Current Report Filing (8-k)
10 Maio 2023 - 9:31AM
Edgar (US Regulatory)
0001349929
false
0001349929
2023-05-09
2023-05-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): May 9, 2023
VYANT
BIO, INC.
(Exact
Name of Company as Specified in its Charter)
| Delaware |
|
001-35817 |
|
04-3462475 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
2
Executive Campus
2370
State Route 70, Suite 310
Cherry
Hill, NJ 08002
(Address
of Principal Executive Offices) (Zip Code)
Company’s
telephone number, including area code (201) 479-1357
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any
of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock |
|
VYNT |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the Company is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Introductory
Note
The
Board of Directors (the “Board”) of Vyant Bio, Inc. (the “Company”), after an assessment of the status of the
Company’s efforts to seek strategic alternatives and the Company’s current cash position, approved a plan on January 31,
2023 to preserve the Company’s cash to be able to continue to pursue a satisfactory strategic alternative for the purpose of maximizing
the value of the Company’s business while also having sufficient cash to adequately fund an orderly wind down of the Company’s
operations (the “Cash Preservation Plan”) in the event it is unable to secure a satisfactory strategic alternative.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
May 9, 2023, the Company and Andrew D. C. LaFrence, the Company’s President, Chief Executive Officer and Chief Financial Officer,
entered into a Consulting Agreement providing that, effective as of June 1, 2023 (or such later date as may be agreement to by the Company
and Mr. LaFrence), Mr. LaFrence would continue to serve as the Company’s President, Chief Executive Officer and Chief Financial
Officer as a part time consultant on an hourly basis rather than a full time employee. His employment agreement, which is filed as an
exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, would be deemed terminated as of that
date by the Company without cause for purposes of determining severance payments thereunder. The Consulting Agreement is seen as a further
step in the Company’s efforts to conserve cash consistent with its Cash Preservation Plan.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
|
VYANT
BIO, INC. |
| |
|
|
|
| Date: |
May
10, 2023 |
By: |
/s/
Andrew D. C. LaFrence |
| |
|
Name: |
Andrew
D. C. LaFrence |
| |
|
Title: |
President,
Chief Executive Officer and Chief Financial Officer |
Cancer Genetics (NASDAQ:CGIX)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Cancer Genetics (NASDAQ:CGIX)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
